At Glenmark Innovation never stops. With our R&D centres across India, Switzerland and the US, we innovate 24 by 7. We consistently meet newer challenges to be able to deliver advances in drug discovery and development while innovating with new chemical and biological entities, across our focus therapy areas of Oncology, Respiratory and Dermatology. We have a strong pipeline of novel molecules in various stages of pre-clinical and clinical development.

With our new drug research and development programme we are now closer than ever in our quest to provide novel solutions to patients facing challenging health conditions. One of the key enablers in research is our cutting-edge proprietary technological platform called BEAT® (Bispecific Engagement by Antibodies based on the T-cell receptor), developed by scientists at our biologics laboratory in Neuchatel, Switzerland for a new range of targeted therapy in cancer treatment.

Joining our R&D team means you get to share ideas, thoughts, and experiences with eminent scientists across NBE (New Biological Entity) team based at Switzerland, NCE (New Chemical Entity) team based in India and the Clinical Development team in the US. With these brilliant minds, innovative technologies and best resources on your side, you can collaborate to fuel discoveries that could transform the paradigms of medical treatment.